We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
+15.1%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$187M
AUM Growth
+$59.7M
(+47%)
Cap. Flow
+$47.7M
Cap. Flow
% of AUM
25.57%
Top 10 Holdings %
Top 10 Hldgs %
63.01%
Holding
43
New
19
Increased
10
Reduced
9
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$21.2M |
| 2 |
Alkermes
ALKS
|
+$13.1M |
| 3 |
Humana
HUM
|
+$6.23M |
| 4 |
Johnson & Johnson
JNJ
|
+$5.36M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$3.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONEM
1Life Healthcare
ONEM
|
+$9.71M |
| 2 |
Prothena Corp
PRTA
|
+$7.24M |
| 3 |
Aldeyra Therapeutics
ALDX
|
+$4.65M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$4.06M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$3.25M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.15% |
| 2 | Industrials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONEM
26
DELISTED
1Life Healthcare
ONEM
| $1.82M | 0.98% |
106,200
-618,800
| -85% | -$9.71M |
|
|
FLNA
27
PUT
Filana Therapeutics
FLNA
$43M
| $1.5M | 0.8% |
+35,900
| New | +$970K |
|
28
BioCryst Pharmaceuticals
BCRX
$2.37B
| $1.43M | 0.77% |
113,800
-62,880
| -36% | -$809K |
|
29
Ardelyx
ARDX
$1.24B
| $1.34M | 0.72% |
1,126,127
-1,037,393
| -48% | -$987K |
|
30
Evolus
EOLS
$394M
| $1.29M | 0.69% |
+160,200
| New | +$1.7M |
|
31
ProQR Therapeutics
PRQR
$243M
| $1.28M | 0.68% |
1,716,290
+8,781
| +0.5% | +$7.05K |
|
32
ADC Therapeutics
ADCT
$146M
| $1.19M | 0.64% |
+247,630
| New | +$1.79M |
|
|
LENZ
33
LENZ Therapeutics
LENZ
$172M
| $1.13M | 0.61% |
+50,921
| New | +$1.21M |
|
34
ARS Pharmaceuticals
SPRY
$590M
| $1.04M | 0.56% |
196,257
-144,851
| -42% | -$714K |
|
35
AbCellera Biologics
ABCL
$1.62B
| $856K | 0.46% |
+86,504
| New | +$949K |
|
|
RCM
36
DELISTED
R1 RCM Inc. Common Stock
RCM
| $595K | 0.32% |
+32,113
| New | +$732K |
|
37
Spok Holdings
SPOK
$221M
| $497K | 0.27% |
+65,000
| New | +$451K |
|
38
Maravai LifeSciences
MRVI
$997M
| $218K | 0.12% |
+8,540
| New | +$214K |
|
39
Cognition Therapeutics
CGTX
$82.3M
| – | – |
-120,198
| Closed | -$254K |
|
40
InMode
INMD
$872M
| – | – |
-45,000
| Closed | -$1.01M |
|
|
APEN
41
DELISTED
Apollo Endosurgery, Inc.
APEN
| – | – |
-90,176
| Closed | -$329K |
|
|
ONEM
42
CALL
DELISTED
1Life Healthcare
ONEM
| – | – |
-440,000
| Closed | -$3.45M |
|
|
GBT
43
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-101,847
| Closed | -$3.25M |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q3 2022 Portfolio in Review
As of Q3 2022, Prosight Management held 43 positions worth $187M, up 47% from $127M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Prosight Management deployed $47.7M of net new capital in Q3 2022, opening 19 new positions and adding to 10 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 303,000 shares worth $18.8M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was 1Life Healthcare, an estimated $9.71M trimmed.
- Prosight Management's largest Q3 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 303,000 shares worth $18.8M.
- Prosight Management added most to Tenet Healthcare in Q3 2022, an estimated $3.04M increase.
- Prosight Management's biggest Q3 2022 reduction was 1Life Healthcare, cutting an estimated $9.71M.
- Prosight Management fully exited Global Blood Therapeutics, Inc. in Q3 2022, selling an estimated $3.25M.
- Prosight Management's ten largest holdings make up 63% of its $187M portfolio in Q3 2022.
- Prosight Management opened 19 new positions and closed 5 in Q3 2022.
- Prosight Management's portfolio value rose 47% quarter-over-quarter to $187M.
Based on Prosight Management's 13F filing for Q3 2022, filed 14 Nov 2022.